AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
5.47
-0.20 (-3.53%)
Jul 24, 2026, 12:18 PM EDT - Market open
AbCellera Biologics Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 79.21 | 75.13 | 28.83 | 38.03 | 485.42 | 375.2 |
Revenue Growth | 242.66% | 160.56% | -24.17% | -92.17% | 29.38% | 60.92% |
Gross Profit Gross Profit Growth | 79.21 | 75.13 | 28.83 | 38.03 | 485.42 | 375.2 |
Operating Income Operating Income Growth | -183.38 | -217.1 | -314.77 | -237.21 | 216.51 | 204.41 |
Net Income Net Income Growth | -135.01 | -146.41 | -162.86 | -146.4 | 158.52 | 153.46 |
Earnings Per Share EPS Growth | -0.48 | -0.49 | -0.55 | -0.51 | 0.50 | 0.48 |
EPS Growth | - | - | - | - | 4.17% | 6.67% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Research Fees Research Fees Growth | 31.26 | 27.21 | 26.28 | 35.56 | 40.8 | 19.08 |
Milestone Payments Milestone Payments Growth | - | 1 | 1.5 | 1.5 | 0.9 | 8 |
Licensing and Royalty Licensing and Royalty Growth | 46.94 | 46.92 | 1.05 | 0.97 | 0.7 | 20.78 |
Revenue (Total) Revenue (Total) Growth | 79.21 | 75.13 | 28.83 | 38.03 | 485.42 | 375.2 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 504.73 | 533.83 | 625.61 | 760.59 | 886.49 | 722.98 |
Total Debt Total Debt Growth | 134.31 | 137.4 | 60.74 | 71.22 | 76.68 | 36.41 |
Net Cash (Debt) Net Cash Growth | 370.42 | 396.42 | 564.87 | 689.36 | 809.81 | 686.56 |
Net Cash Growth | -31.66% | -29.82% | -18.06% | -14.87% | 17.95% | 16.29% |
Net Cash Per Share Net Cash Per Share Growth | 1.23 | 1.33 | 1.92 | 2.38 | 2.57 | 2.16 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -153.26 | -131.3 | -108.56 | -43.88 | 277.36 | 244.58 |
Capital Expenditures CapEx Growth | -35.97 | -42.77 | -78.4 | -76.95 | -70.66 | -58.45 |
Free Cash Flow Free Cash Flow Growth | -189.23 | -174.07 | -186.95 | -120.82 | 206.7 | 186.13 |
Free Cash Flow Growth | - | - | - | - | 11.05% | 1329.91% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -231.52% | -288.98% | -1091.69% | -623.82% | 44.60% | 54.48% |
Pretax Margin | -195.25% | -236.39% | -695.02% | -457.67% | 49.26% | 58.41% |
Profit Margin | -170.45% | -194.88% | -564.83% | -385.00% | 32.66% | 40.90% |
FCF Margin | -238.91% | -231.69% | -648.40% | -317.75% | 42.58% | 49.61% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 20.26 | 29.79 |
Forward PE | - | 60.15 | 60.15 | 60.15 | 60.15 | 51.81 |
P/FCF Ratio | - | - | - | - | 14.06 | 21.76 |
PS Ratio | 21.86 | 13.68 | 30.05 | 43.67 | 5.99 | 10.80 |